Download PDF
Exp Clin Endocrinol Diabetes 2019; 127(07): 437-444
DOI: 10.1055/a-0629-9223
Article
© Georg Thieme Verlag KG Stuttgart · New York

The Role of Different Molecular Markers in Papillary Thyroid Cancer Patients with Acromegaly

Fatma Ela Keskin
1   Division of Endocrinology-Metabolism and Diabetes, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
,
Hande Mefkure Ozkaya
1   Division of Endocrinology-Metabolism and Diabetes, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
,
Sina Ferahman
2   Department of Surgery, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
,
Ozlem Haliloglu
1   Division of Endocrinology-Metabolism and Diabetes, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
,
Adem Karatas
2   Department of Surgery, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
,
Figen Aksoy
3   Department of Pathology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
,
Pinar Kadioglu
1   Division of Endocrinology-Metabolism and Diabetes, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
4   Pituitary Center, Istanbul University, Istanbul, Turkey
› Author Affiliations
Further Information

Publication History

received 31 January 2018
revised 01 April 2018

accepted 14 May 2018

Publication Date:
11 June 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Purpose Prevalence of papillary thyroid cancer (PTC) is increased in patients with acromegaly. We aimed to determine the protein expression of BRAF, RAS, RET, insulin like growth factor 1(IGF1), Galectine 3, CD56 in patients with PTC related acromegaly and to compare the extensity of these expressions with normal PTC patients and benign thyroid nodules.

Methods We studied 313 patients with acromegaly followed in Cerrahpasa Medical Faculty, Endocrinology and Metabolism Clinic between 1998 and 2015. On the basis of availability of pathological specimen of thyroid tissues, thyroid samples of 13 patients from 19 with acromegaly related PTC (APTC), 20 normal PTC and 20 patients with multinodulary goiter (MNG) were histopathologically evaluated. Protein expressions were determined via immunohistochemical staining in ex-vivo tumor samples and benign nodules.

Results The incidence of PTC in acromegaly patients were 6% (n=19). Among patients with PTC, APTC and MNG, all the immunohistochemical protein expressions we have studied were higher in papillary thyroid cancer groups (p<0.01, for all). Between PTC group without acromegaly and APTC, galectin 3 and IGF1 expression was significantly higher in acromegalic patients (p<0.01 for all) while RAS was predominantly higher in PTC patients without acromegaly (p<0.01).

Conclusion BRAF expression was not higher in PTC with acromegaly patients compared to PTC patients without acromegaly. Galectine 3 and IGF1 were expressed more intensively in APTC. These positive protein expressions may have more influence on determining malign nodules among acromegaly patients.

Key words

Acromegaly - papillary thyroid cancer - thyroid nodules
 

  • References

  • 1 Ritvonen E, Loyttyniemi E, Jaatinen P. et al. Mortality in acromegaly: A 20-year follow-up study. Endocr Relat Cancer 2015; 23: 469-480
    PubMedGoogle Scholar
  • 2 Katznelson L, Laws Jr. ER, Melmed S. et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933-3951
    CrossrefPubMedGoogle Scholar
  • 3 Gasperi M, Martino E, Manetti L. et al. Prevalence of thyroid diseases in patients with acromegaly: Results of an Italian multi-center study. J Endocrinol Invest 2002; 25: 240-245
    CrossrefPubMedGoogle Scholar
  • 4 Aydin K, Aydin C, Dagdelen S. et al. Genetic alterations in differentiated thyroid cancer patients with acromegaly. Exp Clin Endocrinol Diabetes 2016; 124: 198-202
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Xing M. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742-762
    CrossrefPubMedGoogle Scholar
  • 6 Hsiao SJ, Nikiforov YE. Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer 2014; 21: T301-T313
    CrossrefPubMedGoogle Scholar
  • 7 Kim HK, Lee JS, Park MH. et al. Tumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with acromegaly. PLoS One 2014; 9: e110241
    CrossrefPubMedGoogle Scholar
  • 8 Gydee H, O'Neill JT, Patel A. et al. Differentiated thyroid carcinomas from children and adolescents express IGF-I and the IGF-I receptor (IGF-I-R). Cancers with the most intense IGF-I-R expression may be more aggressive. Pediatr Res 2004; 55: 709-715
    CrossrefPubMedGoogle Scholar
  • 9 van der Laan BF, Freeman JL, Asa SL. Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 1995; 5: 67-73
    CrossrefPubMedGoogle Scholar
  • 10 Gullu BE, Celik O, Gazioglu N. et al. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 2010; 13: 242-248
    CrossrefPubMedGoogle Scholar
  • 11 Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer?. Clin Endocrinol (Oxf) 2006; 64: 115-121
    CrossrefPubMedGoogle Scholar
  • 12 Chiu CG, Strugnell SS, Griffith OL. et al. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010; 176: 2067-2081
    CrossrefPubMedGoogle Scholar
  • 13 Keller S, Angrisano T, Florio E. et al. DNA methylation state of the galectin-3 gene represents a potential new marker of thyroid malignancy. Oncol Lett 2013; 6: 86-90
    CrossrefPubMedGoogle Scholar
  • 14 Nechifor-Boila A, Borda A, Sassolas G. et al. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56. Pathol Res Pract 2013; 209: 585-592
    CrossrefPubMedGoogle Scholar
  • 15 Barut F, Onak Kandemir N, Bektas S. et al. Universal markers of thyroid malignancies: Galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol 2010; 21: 80-89
    CrossrefPubMedGoogle Scholar
  • 16 Nasr MR, Mukhopadhyay S, Zhang S. et al. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol 2006; 19: 1631-1637
    PubMedGoogle Scholar
  • 17 El Demellawy D, Nasr AL, Babay S. et al. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. Pathol Res Pract 2009; 205: 303-309
    CrossrefPubMedGoogle Scholar
  • 18 Scarpino S, Di Napoli A, Melotti F. et al. Papillary carcinoma of the thyroid: Low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol 2007; 212: 411-419
    CrossrefPubMedGoogle Scholar
  • 19 Tita P, Ambrosio MR, Scollo C. et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf) 2005; 63: 161-167
    CrossrefPubMedGoogle Scholar
  • 20 Mian C, Ceccato F, Barollo S. et al. AHR over-expression in papillary thyroid carcinoma: Clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up. PLoS One 2014; 9: e101560
    CrossrefPubMedGoogle Scholar
  • 21 Roger P, Taton M, Van Sande J. et al. Mitogenic effects of thyrotropin and adenosine 3',5'-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab 1988; 66: 1158-1165
    CrossrefPubMedGoogle Scholar
  • 22 Kimura T, Dumont JE, Fusco A. et al. Insulin and TSH promote growth in size of PC Cl3 rat thyroid cells, possibly via a pathway different from DNA synthesis: Comparison with FRTL-5 cells. Eur J Endocrinol 1999; 140: 94-103
    PubMedGoogle Scholar
  • 23 Volzke H, Friedrich N, Schipf S. et al. Association between serum insulin-like growth factor-I levels and thyroid disorders in a population-based study. J Clin Endocrinol Metab 2007; 92: 4039-4045
    CrossrefPubMedGoogle Scholar
  • 24 Ock S, Ahn J, Lee SH. et al. IGF-1 receptor deficiency in thyrocytes impairs thyroid hormone secretion and completely inhibits TSH-stimulated goiter. FASEB J 2013; 27: 4899-4908
    CrossrefPubMedGoogle Scholar
  • 25 Maiorano E, Ciampolillo A, Viale G. et al. Insulin-like growth factor 1 expression in thyroid tumors. Appl Immunohistochem Mol Morphol 2000; 8: 110-119
    PubMedGoogle Scholar
  • 26 Malaguarnera R, Morcavallo A, Belfiore A. The insulin and igf-I pathway in endocrine glands carcinogenesis. J Oncol 2012; 2012: 635614
    PubMedGoogle Scholar
  • 27 Chiloeches A, Marais R. Is BRAF the Achilles' Heel of thyroid cancer?. Clin Cancer Res 2006; 12: 1661-1664
    CrossrefPubMedGoogle Scholar
  • 28 Espinosa AV, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Br J Cancer 2007; 96: 16-20
    CrossrefPubMedGoogle Scholar
  • 29 Soares P, Trovisco V, Rocha AS. et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 2004; 444: 572-576
    PubMedGoogle Scholar
  • 30 Zhu Z, Ciampi R, Nikiforova MN. et al. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: Effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 2006; 91: 3603-3610
    CrossrefPubMedGoogle Scholar
  • 31 Chua EL, Wu WM, Tran KT. et al. Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. J Clin Endocrinol Metab 2000; 85: 2733-2739
    PubMedGoogle Scholar
  • 32 Chiappetta G, Toti P, Cetta F. et al. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab 2002; 87: 364-369
    CrossrefPubMedGoogle Scholar
  • 33 Ishizaka Y, Kobayashi S, Ushijima T. et al. Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene 1991; 6: 1667-1672
    PubMedGoogle Scholar
  • 34 Dunderovic D, Lipkovski JM, Boricic I. et al. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature. Diagn Pathol 2015; 10: 196
    CrossrefPubMedGoogle Scholar
  • 35 Cvejic D, Savin S, Petrovic I. et al. Galectin-3 expression in papillary microcarcinoma of the thyroid. Histopathology 2005; 47: 209-214 2012; 2012: 635614
    CrossrefPubMedGoogle Scholar
  • 36 Gweon HM, Kim JA, Youk JH. et al. Can galectin-3 be a useful marker for conventional papillary thyroid microcarcinoma?. Diagn Cytopathol 2016; 44: 103-107
    CrossrefPubMedGoogle Scholar
  • 37 Kim ES, Lim DJ, Lee K. et al. Absence of galectin-3 immunostaining in fine-needle aspiration cytology specimens from papillary thyroid carcinoma is associated with favorable pathological indices. Thyroid 2012; 22: 1244-1250
    CrossrefPubMedGoogle Scholar
  • 38 Radu TG, Mogoanta L, Busuioc CJ. et al. Histological and immunohistochemical aspects of papillary thyroid cancer. Rom J Morphol Embryol 2015; 56: 789-795
    PubMedGoogle Scholar
  • 39 El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 2008; 3: 5
    CrossrefPubMedGoogle Scholar
  • 40 Ozolins A, Narbuts Z, Strumfa I. et al. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules. Medicina (Kaunas) 2012; 48: 507-514
    PubMedGoogle Scholar